New advances in immunotherapy for non-small cell lung cancer

New advances in immunotherapy for non-small cell lung cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P932PMC publication ID6129543
P698PubMed publication ID30210667

P2093author name stringHui Liu
Xin Pan
Fang Wang
Shasha Wang
Zhen Zeng
Hongjun Gao
Haifeng Qin
P2860cites workSafety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerQ24633070
The PD-1 pathway in tolerance and autoimmunityQ24633549
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4Q24634871
CTLA-4 ligation blocks CD28-dependent T cell activationQ24678229
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialQ27853359
Cancer statistics, 2015Q27860576
The blockade of immune checkpoints in cancer immunotherapyQ27860852
CEACAM1 regulates TIM-3-mediated tolerance and exhaustionQ28115443
PD-1 and its ligands in tolerance and immunityQ28131650
CTLA-4 can function as a negative regulator of T cell activationQ28235866
T cell exclusion, immune privilege, and the tumor microenvironmentQ28259872
Induction of microsatellite instability by oxidative DNA damageQ28285253
Molecular basis of T cell inactivation by CTLA-4Q28291723
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsQ29617771
Cancer immunotherapy comes of ageQ29619918
Pembrolizumab for the treatment of non-small-cell lung cancerQ29620851
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerQ29620902
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerQ29620913
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.Q30275719
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune diseaseQ34112417
Immunotherapy for Metastatic Solid CancersQ34219970
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.Q34272038
Role of LAG-3 in regulatory T cells.Q34358935
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.Q34891171
Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-AnalysisQ35836471
Tissue expression of PD-L1 mediates peripheral T cell tolerance.Q36228541
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerQ36352827
Roles of LAG3 and EGR2 in regulatory T cells.Q37998328
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialQ38364028
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 StudyQ38372125
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trialQ38375220
Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challQ38649110
Monitoring immune-checkpoint blockade: response evaluation and biomarker developmentQ38666241
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.Q38669328
IFNγ-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor MicroenvironmentQ38699928
Human mismatch repair system balances mutation rates between strands by removing more mismatches from the lagging strandQ38781896
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.Q38837469
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerQ38975751
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.Q39048866
Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyQ39130451
Wnt/beta-catenin pathway: modulating anticancer immune responseQ39286193
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialQ40163779
Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer ManagementQ40226483
Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancerQ40318832
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.Q40408396
Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma.Q40475767
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC StudyQ40717466
KIR expression on self-reactive CD8+ T cells is controlled by T-cell receptor engagementQ40902154
ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical OncologyQ47593980
Analysis of somatic microsatellite indels identifies driver events in human tumors.Q47823632
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung CancerQ47834638
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung CancerQ47884056
BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancerQ50886634
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.Q51372253
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.Q51616377
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectimmunotherapyQ1427096
non-small-cell lung carcinomaQ3658562
P304page(s)2234-2245
P577publication date2018-01-01
P1433published inAmerican Journal of Translational ResearchQ4744272
P1476titleNew advances in immunotherapy for non-small cell lung cancer
P478volume10

Reverse relations

cites work (P2860)
Q95817979An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient
Q64230139Comprehensive clinical implications of homeobox A10 in 3,199 cases of non-small cell lung cancer tissue samples combining qRT-PCR, RNA sequencing and microarray data
Q91793306Convex probe endobronchial ultrasound: historical, contemporary, and cutting-edge applications
Q92887334Dendritic cells fused with endothelial progenitor cells play immunosuppressive effects on angiogenesis in acute myeloid leukemia mice
Q89897669Downregulation of hsa-microRNA-204-5p and identification of its potential regulatory network in non-small cell lung cancer: RT-qPCR, bioinformatic- and meta-analyses
Q92024293Hsa_circ_0002483 inhibited the progression and enhanced the Taxol sensitivity of non-small cell lung cancer by targeting miR-182-5p
Q91812593Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion
Q92603937MiR-34c acts as a tumor suppressor in non-small cell lung cancer by inducing endoplasmic reticulum stress through targeting HMGB1
Q92934599Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer

Search more.